Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V. — Clinical Trial Site

22 Registered trials

8 Currently recruiting

Organisation

Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.

Location

Bonn, Germany

Identifier

ORG-100043714

Address

Venusberg-Campus 1/99, Venusberg, 53127, Germany

Departments

-
#40138: Clinical Research Platform - CRP
3005 : NA
Clinical Trial Unit
Department of Neurology
Department of Neurology, University of Ulm, and Department of Neurological Rehabilitation
Department of Psychiatry and Neurosciences
Department of Psychiatry and Psychotherapy
Dept. of Neurogenerative Diseases and Geriatric Psychiatry
Deutsches Zentrum Fuer Neurodegenerative Erkrankungen e.V.
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Klinik für Alterspsychiatrie und Kognitive Störungen
Klinik für Neurodegenerative Erkrankungen
N/A
NA
Neurodegenerative Erkrankung
Neurology
Translational Dementia Research Group
Zentrum für Klinische Forschung des DZNE e.V.

Clinical trials at this site (22)

Search interface

A Study to Assess if BIIB080 Can Change Clinical Dementia Rating-Sum of Boxes Scores, and BIIB080 Safety and Tolerability When Injected Into… Not authorised

2022-501644-15-00 Mild Cognitive Impairment due to Alzheimer's Disease Al 4
A double-blinded, randomized, placebo-controlled, multi-center trial of Efgartigimod in autoimmune dementia (EfgaDem) Pending

2023-510216-39-00 Autoimmune dementia 4
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With … Pending

2024-513579-42-00 Type 1 Myotonic Dystrophy 7
A Study of Treatments for the Prevention of Disease Progression in Individuals at Risk for or With Early Onset Alzheimer’s Disease Caused by… Pending

2024-517187-36-01 Dominantly Inherited Alzheimer’s Disease (DIAD) 10
A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease Pending

2025-521113-13-00 Early Parkinson’s Disease 10
A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participant… Pending

2025-523481-24-00 Participants with Progressive Supranuclear Palsy Richar 5
An Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518006-40-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-13
A Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD) Recruiting

2024-518008-33-00 Early Symptomatic Alzheimer’s Disease (MCI to Mild Deme 5 2025-11-12
A Study to Evaluate ALN-HTT02 in Adult Patients with Huntington’s Disease Recruiting

2024-515732-68-00 Huntington’s disease 1 2025-03-07
Study of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1 Recruiting

2023-509748-89-00 Facioscapulohumeral muscular dystrophy (FSHD) 7 2025-02-19
Patient- and care-related benefits of amyloid PET imaging (ENABLE) Recruiting

2023-503705-10-00 Dementia in Pick disease 6 2024-08-19
Evaluation of the efficacy and safety of Rituximab in patients with Amyotrophic Lateral Sclerosis (ALS) Recruiting

2022-502743-35-00 Sporadic Amyotrophic Lateral Sclerosis 4 2024-04-22
A phase 1/2a, open-label trial to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses o… Recruiting

2024-514328-18-00 Spinocerebellar ataxia types 1, 3 and Huntington's dise 7 2022-12-06
Efficacy and Safety Study of Nipocalimab for Adults with CIDP Recruiting

2023-508425-28-00 Chronic Inflammatory Demyelinating Polyneuropathy 4 2022-10-24
A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzhe… Ended

2022-501644-15-01 Mild Cognitive Impairment due to Alzheimer's Disease Al 4 2023-09-28
A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF QRL-20… Ended

2022-500758-41-00 Amyotrophic lateral sclerosis 1 2023-08-15
A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants with Prodromal and Early Manife… Ended

2023-503928-10-00 Prodromal and Early Manifest Huntington’s Disease 4 2023-02-01
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Early… Ended

2024-515198-91-00 Dominantly Inherited Alzheimer Disease (DIAD) 10 2022-12-20
A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-6404… Halted

2023-505096-68-00 Preclinical Alzheimer’s Disease 4 2025-01-14
STRIDES - A Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia Ended

2022-501004-10-00 Spinocerebellar Ataxia type-3 (SCA3) 10 2023-01-30
An extension of the orchestra (PD0053) study to learn how safe minzasolmin is and if it works long-term in participants with Parkinson’s dis… Ended

2022-500424-30-00 Parkinson’s disease 4 2022-12-28
A Study to evaluate Efficacy, Safety, Tolerability and Effects of TAK-341 in the human body in patients with Multiple System Atrophy Ended

2023-509876-40-00 Multiple System Atrophy 4 2022-11-22